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The expression of the chemokine receptor XCR1 and
the function of its ligand XCL1 (otherwise referred to
as ATAC, lymphotactin, or SCM-1) remained elusive
to date. In the present report we demonstrated that
XCR1 is exclusively expressed on murine CD8+
dendritic cells (DCs) and showed that XCL1 is a
potent and highly specific chemoattractant for this
DC subset. CD8+ T cells abundantly secreted XCL1
8–36 hr after antigen recognition on CD8+ DCs
in vivo, in a period in which stable T cell-DC interac-
tions are known to occur. Functionally, XCL1 in-
creased the pool of antigen-specific CD8+ T cells
and their capacity to secrete IFN-g. Absence of
XCL1 impaired the development of cytotoxicity to
antigens cross-presented by CD8+ DCs. The XCL1-
XCR1 axis thus emerges as an integral component
in the development of efficient cytotoxic immunity
in vivo.
INTRODUCTION
In the immune system, intercellular communication is facilitated
by chemokines. Structurally, chemokines can be grouped into
the CX3C, CXC, CC, and C families (Zlotnik and Yoshie, 2000).
Some of the chemokines are expressed constitutively and are
involved primarily in the organization of lymphoid tissue
(‘‘homeostatic’’ chemokines), and others are mainly involved in
the orchestration of an inflammatory response (‘‘inflammatory’’
chemokines). Activation-induced, T cell-derived, and chemo-
kine-related cytokine (ATAC), the only member of the C family
of chemokines, was cloned by our laboratory (Mu¨ller et al.,
1995), and independently as lymphotactin (Kelner et al., 1994)
and SCM-1 (Yoshida et al., 1995), and was later given the official
designation XCL1 (Zlotnik and Yoshie, 2000). XCL1, a polypep-
tide of 93 aa (Dorner et al., 1997), is secreted by CD8+ T cells,
Th1 cell-polarized CD4+ T cells (Dorner et al., 2002), and NK cells
(Dorner et al., 2004) upon activation. Cosecretion of XCL1 with
IFN-g and the inflammatory chemokines MIP-1a, MIP-1b, andRANTES by CD8+ T cells and NK cells in several infection models
strongly suggested that XCL1 is an integral part of the Th1 cell
immune response (Dorner et al., 2002, 2004).
XCL1 has originally been described as a chemoattractant for
thymocytes and T lymphocytes (Kelner et al., 1994; Kennedy
et al., 1995), and later for a variety of other cell types, including
B cells and NK cells, but this function could not be substantiated
by others (Dorner et al., 1997; Yoshida et al., 1998; Bleul et al.,
1996) (for an extensive list of positive and negative reports on
chemotactic properties of XCL1, see Table S1 available online).
XCR1 is the only receptor for XCL1 (Yoshida et al., 1998). In the
absence of XCR1-specific antibodies, expression of XCR1 had
to be measured by PCR and was reported in a variety of cell
types, including T cells, B cells, and NK cells (see Table S2).
However, apparent detection of XCR1 did not match the
(disputed) function of XCL1 reported by others, so the role of
XCL1 in the immune system remained elusive to date.
Dendritic cells (DCs) present antigen to naive T cells and thus
prime them for immune function. ‘‘Migratory’’ DCs, among them
interstitial DCs or Langerhans’ cells, reside in the periphery, take
up antigen there, and transport it to lymph nodes (LN) for presen-
tation. ‘‘Resident’’ DCs, which make up the large majority of
splenic and thymic DCs, take up antigen locally and present it
to T cells ‘‘on site.’’ Resident DCs, which all express the CD11c
cell surface protein, can be subdivided into CD11bhiCD4+
CD8CD205lo DCs (‘‘CD4+ DCs,’’ around 70% of splenic DCs),
CD11bloCD8+CD205hi DCs (‘‘CD8+ DC,’’ 20%), and CD11bhi
CD4CD8CD205lo DCs (‘‘DN’’ DCs, 10%) (Vremec et al., 2000).
The relative roles of the various DC subtypes in antigen
presentation is at present only partially understood, but it is clear
that resident CD8+ DCs are critically involved in antigen ‘‘cross-
presentation,’’ in which exogenous antigen is not ‘‘classically’’
presented in the context of MHC class II, but instead shunted
to the MHC class I pathway. Cross-presentation to T cells (den
Haan et al., 2000; Heath et al., 2004) has been shown to be of
major importance in the defense against viral and bacterial path-
ogens, and also in the recognition of tumor antigens (Huang
et al., 1994).
In the present report, we identified XCL1 as a potent chemo-
kine with a selective action on CD8+ DCs. These functional
results are in line with extensive whole-body expression anal-
yses strongly indicating an exclusive utilization of XCR1 byImmunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc. 823
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abundantly secrete XCL1 8–36 hr after encountering antigen
on CD8+ DCs and demonstrated that this XCL1 secretion is
required for optimal expansion and differentiation of CD8+
T cells to cytotoxic and IFN-g-secreting cells in vivo.
RESULTS
The Chemokine Receptor XCR1 Is Selectively
Expressed in CD8+ DCs
All published data indicating a seemingly broad expression of
murine or human XCR1 in the immune system (see Table S2)
were obtained with total RNA and standard RT-PCR utilizing
primers designed on the basis of the only exon known at that
time (now exon 2). Recently, a new putative exon 1 for the murine
XCR1 has been identified (Figure 1A, GenBank NC_000075).
Analysis of splenic RNA by standard RT-PCR via primers F1
and R1 (Figure 1A) gave the expected product of 136 bp
(Figure 1B) and thus demonstrated that XCR1 exon 1 is tran-
scribed and spliced to exon 2. We thus could set up a highly
sensitive and specific quantitative RT-PCR (qRT-PCR) spanning
the large intron. This assay gave a very low XCR1 signal with total
RNA obtained from C57BL/6 spleen, but no signal with RNA from
highly purified resting or activated primary CD8+ T cells, CD4+
T cells, B cells, NK cells, or plasmacytoid DCs (pDCs) (Figure 1C).
A strong XCR1 signal was obtained with RNA from CD8+ DCs,
and a very low signal with CD8 DCs (Figure 1C; for phenotypic
definition of these populations see Figure 4A). Identical qualita-
tive and quantitative results were obtained with an independent
RT-qPCR system based on exon 2 only (Figure 1A), but only
when poly(A)RNA was used instead of total RNA (indicating
that previous reports on a broad expression of XCR1 were based
on assays that were likely contaminated with genomic DNA). The
same results were obtained with cells from BALB/c and 129SV
mice (not shown). These experiments revealed, within the tested
populations, an essentially selective expression of XCR1 mRNA
in CD8+ DCs.
XCL1 Mobilizes Calcium in CD8+ DCs
but Not in CD8 DCs
To test XCL1 for function on XCR1-bearing cells, primary splenic
CD8+ DCs and CD8 DCs were isolated to a purity >96% by
flow sorting. When exposed to XCL1, CD8+ DCs reacted by
vigorous calcium mobilization, whereas CD8 DCs failed to re-
spond under identical conditions (Figure 2). No calcium re-
sponse was observed with CD8+ DCs from homozygous
B6.XCR1-lacZ mice, which lack the XCR1 receptor (not shown).
These results indicated that XCR1 is expressed on the cell
surface of CD8+ DCs and also demonstrated the capacity of
XCR1 to transduce an activation signal through binding of its
chemokine ligand.
XCL1 Is a Chemoattractant for CD8+ DCs,
but Not for CD8 DCs, T Cells, B Cells, or NK Cells
To test XCL1 for chemotaxis, splenic DCs were enriched for
CD11c+ cells. The resulting population, containing approxi-
mately 23% CD8+ DCs and 70% CD8 DCs (Figure 3A, ‘‘input
DC’’), exhibited only a low background migration in a transwell
system. Upon addition of increasing amounts of XCL1, a selec-
tive migration of CD8+ DCs was observed (Figure 3A). At the
optimal concentration of XCL1 (100 ng/ml), more than 30% of
all input CD8+ DCs had migrated (Figures 3A and 3B), whereas
less than 5% of the input CD8 DCs migrated under any of the
conditions tested (Figure 3B). Controls with CCL21 ensured
that the unresponsiveness of CD8 DCs to XCL1 was not caused
by a general unresponsiveness of this DC subset (Figure 3B).
Similar migration results were obtained with DC subsets from
inguinal and popliteal LN (data not shown). Checkerboard
Figure 1. The Chemokine Receptor XCR1 Is Selectively Expressed
in CD8+ DCs
(A) Organization of the murine Xcr1 gene. E1, exon 1; E2, exon 2. Primer sets
used for expression analyses are indicated.
(B) A PCR product of 136 bp obtained by standard RT-PCR of total RNA from
spleen with primers F1 and R1. RT, reverse transcriptase.
(C) Quantitative RT-PCR of total RNA from C57BL/6 spleen, resting and
activated CD8+ and CD4+ T cells, B cells, NK cells, resting CD8 DCs, CD8+
DCs, and pDCs via primers F1, R1, and probe P1. An independent qRT-PCR
performed with poly(A)RNA obtained from the same cells, and in addition
from granulocytes (primers F2, R2, probe P2), gave identical results (data
not shown).
Figure 2. XCL1 Induces a [Ca2+]i Signal in CD8
+, but Not in CD8,
DCs
CD8+ or CD8 DCs were flow-sorted to a purity >96%, immobilized on poly-L-
lysine-coated glass coverslips, and loaded with fura-2/AM (2 mM). Cells were
imaged in a monochromator-assisted digital video imaging system and chal-
lenged with 1000 ng/ml XCL1 as indicated (arrow). Data represent intracellular
Ca2+ concentrations ([Ca2+]i) in 45–56 single cells (gray lines) measured in three
independent experiments. Mean [Ca2+]i signal averaged over all cells
measured is indicated (black lines).824 Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc.
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lower and upper wells of the transwell system, indicated true
chemotaxis and not only chemokinesis (not shown). The exper-
iments shown were performed with chemically synthesized
XCL1; identical results (not shown) were obtained with natural
XCL1 (supernatants of a murine XCL1-transfectant or superna-
tants of activated CD8+ T cells). To exclude the involvement of
another receptor mediating the XCL1-induced chemotaxis, we
also tested DCs from mice in which the Xcr1 gene has been
replaced by a LacZ-reporter gene coding for b-galactosidase
(‘‘B6.XCR1-lacZ’’). CD8+ DCs from heterozygous mice (contain-
ing one intact Xcr1 allele) still exhibited substantial migration to
XCL1, whereas CD8+ DCs from homozygous B6.XCR1-lacZ
mice no longer responded (Figure 3C). In the literature, migration
of T cells, B cells, and NK cells was repeatedly reported in
response to XCL1. When we performed analogous transwell
experiments, XCL1 failed to induce migration with any of these
cell populations, whereas positive controls were effective (Fig-
ure 3D). Together, these experiments established that XCL1
is a chemokine that selectively attracts CD8+ DCs. Further, the
Figure 3. XCL1 Induces Chemotaxis via
XCR1 in CD8+ DCs, but Not in CD8 DCs, T
Cells, B Cells, or NK Cells
(A) Highly enriched splenic DCs (CD11c+ cells >
90%, ‘‘input DC’’) were tested for migration in
response to medium alone or serial dilutions of
XCL1 (1–1000 ng/ml) in a transwell system. The
chemokine CCL21 (500 ng/ml) was used as a posi-
tive control for CD8 DCs. The input and migrated
cell populations were analyzed for expression of
CD8, CD11b, and CD11c by flow cytometry;
shown are cells gated on CD11c. The absolute
numbers of CD8+CD11b DCs (‘‘CD8+ DC’’) and
CD8CD11b+ DCs (‘‘CD8 DC’’) in input and
migrated cell populations are represented in the
dot plots, because all cells were included in the
analysis in each instance.
(B) Proportion of migrated CD8+ DCs and CD8
DCs relative to the input CD8+ DCs and CD8
DCs in the experiment shown in (A).
(C) Proportion of migrated wild-type CD8+ DCs
(‘‘Xcr1+/+ CD8+ DC’’), heterozygous (‘‘Xcr1+/
CD8+ DC’’), and homozygous CD8+ DCs (‘‘Xcr1/
CD8+ DC’’) from B6.XCR1-lacZ mice in response
to XCL1 (100 ng/ml).
(D) Proportion of migrated T cells, B cells, or NK
cells in response to XCL1 (1–1000 ng/ml) or
the chemokines CCL21 (100 ng/ml), CXCL12
(200 ng/ml), or CXCL9 (200 ng/ml) used as positive
controls. All experiments were performed at least
twice.
Data in (B)–(D) are presented as mean ± SEM.
results demonstrated that XCL1 exerts its
chemotactic action exclusively through
its receptor XCR1.
XCR1 Is Expressed in 70%–85%
of Splenic CD8+ DCs
In order to determine whether XCR1 is
expressed in all or only a subpopulation
of CD8+ DCs, we further examined homozygous B6.XCR1-lacZ
mice. Splenic cells were loaded with fluorescein-di-b-D-galacto-
pyranoside (FDG) and analyzed by flow cytometry. A signal was
routinely detected in 70%–85% of splenic CD8+ DCs (and highly
correlated with CD103 and CD205) and in a small proportion
(2%–8%) of CD4CD8 DCs (associated to 50% with CD103
and correlated with CD205); all other splenic cell types, including
CD4+ DCs, were negative (Figure 4A and not shown). Similar
data were obtained with heterozygous LacZ reporter mice (not
shown). Taken together, these LacZ-reporter data indicated
that in the spleen, XCR1 is exclusively expressed in CD8+ DCs
(70%–85%) and a small subset (2%–8%) of CD4CD8 DCs.
Whole-Body Analysis Indicates Selective Expression
of XCR1 in Cross-presenting Splenic DCs
and Corresponding Cells in Other Organs
Flow cytometry and standard histological examination of homo-
zygous B6.XCR1-lacZ reporter mice (lacking the XCR1 receptor)
revealed an apparently undisturbed organ development and
a normal immune cell composition, including DC subsetsImmunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc. 825
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tosidase activity gave signals in the red pulp, the marginal zones,
and in central areas of T cell zones (Figure 4B), and thus corre-
sponded to the distribution of CD8+CD205+ DCs in the spleen
(McLellan et al., 2002; Idoyaga et al., 2009). In lymph nodes,
LacZ signals were identified in the subcapsular sinus and in
the paracortical areas (Figure 4B). LacZ+ cells were further found
Figure 4. XCR1 Expression in the Spleen
and Lymph Nodes
(A) Splenocytes from homozygous B6.XCR1-lacZ
mice, in which both XCR1 genes are replaced by
LacZ-reporter genes, were loaded with fluores-
cein-di-b-D-galactopyranoside (FDG), a fluoro-
genic substrate for b-galactosidase, and analyzed
by flow cytometry. Various cell subsets were
analyzed for FDG-fluorescence, shown are
CD11chiMHC-IIhi CD4+ DCs, CD4CD8 DCs,
and CD8+ DCs, after staining for CD103 and
CD205 (top rows, the inset numbers indicate
percentage of cells). The background signal
obtained after loading splenocytes from wild-
type C57BL/6 mice with FDG is given in the lower
rows. Shown is a representative experiment out of
three. Identical results were obtained with hetero-
zygous B6.XCR1-lacZ mice (not shown).
(B) XCR1 tissue distribution was determined in the
spleen and the axillary lymph node of homozygous
B6.XCR1-lacZ mice with X-gal, a chromogenic
substrate for b-galactosidase. Similar results
were obtained with heterozygous B6.XCR1-lacZ
mice (not shown). No signals were detected in
tissues of wild-type C57BL/6 animals.
in all lymphoid tissues, where they repre-
sented a fraction of CD11c+ cells (as
determined in serial sections, not shown).
A systematic analysis of nonlymphoid
organs and tissues (see Experimental
Procedures) revealed only very few
LacZ+ CD11c+ cells, and their apearance
and anatomical location suggested
tissue-resident DCs. These histological
results, when taken together with the
qRT-PCR and the flow cytometry data,
demonstrated that XCR1 expression in
the mouse is essentially restricted to
splenic CD8+ DCs and to apparently
similar cells in other lymphoid and non-
lymphoid organs. Analogous data were
obtained with heterozygous LacZ mice
(not shown).
Normal Immune Cell Distribution
in XCL1-Deficient Mice
To assess the overall biological role of the
XCL1 chemokine-XCR1 receptor system
in vivo, we generated Xcl1-deficient mice
and backcrossed them to the C57BL/6
background. Homozygous Xcl1/ mice
no longer produced XCL1 mRNA or
protein (see also Figure 5B). Xcl1/ animals showed normal
fertility and viability and had an apparently normal organ devel-
opment and immune cell composition. More specifically, the
frequency of DC subsets in the spleen and LN appeared normal
(see Table S3). These results with Xcl1/ mice, congruent with
the data obtained with homozygous B6.XCR1-lacZ mice, indi-
cated that XCL1 does not play a major role in the development826 Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc.
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lymphoid tissues.
Antigen-Dependent Induction of XCL1 in CD8+ T Cells
In Vivo
We analyzed the induction of the XCL1 chemokine protein in
CD8+ T cells in vivo. OT-I T cells, bearing a transgenic T cell
receptor for ovalbumin (OVA), were adoptively transferred into
C57BL/6 syngeneic recipients. Twenty-four hours later, the
recipients were injected i.v. with OVA coupled to a DEC-205-
specific mAb (aDEC-205:OVA), thus targeting OVA to CD8+
DCs, together with a CD40 mAb, which induces maturation of
DCs (Bonifaz et al., 2002). In preliminary experiments we had
determined that XCR1 mRNA continues to be expressed under
these immunization conditions (data not shown). Spleens were
removed at defined time points and OT-I T cells were analyzed
for secretion of XCL1 after incubation with Brefeldin A, but
without further restimulation. XCL1 secretion started at around
6 hr after antigen delivery, peaked at 12 hr with around 75% of
OT-I T cells secreting XCL1, and reached a plateau between
24 and 48 hr (Figures 5A and 5C). The kinetics of XCL1 secretion
paralleled the expression of CD69 and CD25 on OT-I T cells
(Figure 5C), and the three signals were highly correlated in single
OT-I cells in the first 24 hr (Figure 5B, upper histogram, and not
shown). The specificity of the intracellular staining for XCL1 was
verified by comparing the signals in Xcl1+/+ OT-I T cells
(Figure 5A, black histograms) with signals in Xcl1/ OT-I
T cells (Figure 5A, gray histograms), as detailed for the 12 hr
time point (Figure 5B). Interestingly, the percentage of OT-I
T cells secreting XCL1 was dependent on the dose of antigen in-
jected (Figure 5D), whereas the time point of initial XCL1 secretion
was not (Figure 5E). The amount of XCL1 secreted per cell was
correlated to the strength of the antigenic signal (Figure 5F). Over-
all, these experiments determined that activated CD8+ T cells
secrete XCL1 over the entire period of time in which intense
T cell-DC interactions occur (Mempel et al., 2004).
Absence of XCL1 Leads to a Decreased Pool Size
of CD8+ T Cells Reacting to Antigen Cross-presented
by CD8+ DCs
In order to examine any influence of XCL1 on CD8+ T cell priming
and expansion under tolerizing and immunizing conditions,
Figure 5. Kinetics and Dose Dependence of
XCL1 Secretion by CD8+ T Cells upon
Recognition of Antigen Presented by CD8+
DCs In Vivo
(A) OT-I T cells were transferred into syngeneic
mice, 24 hr later the recipients were immunized
by i.v. injection of 100 ng LPS-free aDEC-
205:OVA and 6 mg CD40 mAb. XCL1 expression
was analyzed in OT-I T cells (gated on the expres-
sion of the surface markers CD90.1 and CD8) from
spleens removed at 3, 6, 12, 24, and 48 hr after
immunization (bold histograms); background
stainings obtained with Xcl1/ OT-I T cells under
the same conditions are represented by gray
histograms. The inset numbers give the mean fluo-
rescence intensity (MFI) of the signal in Xcl1+/+
OT-I T cells.
(B) The correlation between the staining for XCL1
and CD69 in wild-type OT-I T cells (‘‘Xcl1+/+ OT-I,’’
upper histogram) and Xcl1-deficient OT-I T cells
(‘‘Xcl1/ OT-I,’’ lower histogram) is detailed for
the 12 hr time point.
(C) Proportion of XCL1-secreting wild-type OT-I
T cells in the time-course experiment depicted in
(A) correlated to the proportion of cells expressing
the surface markers CD69 and CD25. Shown is
a representative experiment of two.
(D) Proportion of XCL1-secreting OT-I T cells 8 hr
after injection of increasing amounts of antigen
(12.5, 25, 50, 100, 200, 400 ng aDEC-205:OVA).
(E) Time point of initial XCL1-secretion after injec-
tion of 25, 100, and 400 ng aDEC-205:OVA.
In experiments (D) and (E), aDEC-205:OVA was in-
jected without the CD40 mAb.
(F) Mean fluorescence intensity (MFI) of the XCL1
signal in cells secreting this chemokine in the
experiment shown in (E).
All experiments were performed at least twice.
Data in (C)–(F) are presented as mean ± SEM.Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc. 827
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Xcl1/ C57BL/6 and wild-type C57BL/6 mice, respectively.
Recipient mice were injected 24 hr later with LPS-free aDEC-205:
OVA conjugate alone (‘‘tolerization’’), or with aDEC-205:OVA in
combination with CD40 mAb (‘‘immunization’’) (Bonifaz et al.,
2002). Cell division analysis of OT-I Xcl1+/+ and OT-I Xcl1/
T cells via CFSE labeling and also analysis of apoptosis markers
revealed some differences, but these were too small to allow
clear conclusions. We therefore measured a functional end-point
in the experimental system used, the size of the OT-I T cell pool.
Three days after injection of aDEC-205:OVA alone, the
frequency of Xcl1/ OT-I T cells in the spleens of recipient
animals was marginally reduced when compared to Xcl1+/+
OT-I T cells (Figure 6A). However, upon injection of aDEC-
205:OVA in combination with CD40 mAb, the difference in
frequency rose to approximately 40% (Figure 6A). Twelve days
after antigen delivery, at a time point when the initially expanded
T cell population had contracted again, tolerization with aDEC-
205:OVA reduced OT-I T cell numbers to a point that they were
barely detectable, as described earlier (Bonifaz et al., 2002),
Figure 6. Influence of XCL1 on the Activa-
tion of T Cells Interacting with CD8+ DCs
and Their Pool Size
(A) Xcl1+/+ (filled circles) or Xcl1/ (open triangles)
OT-I T cells were adoptively transferred into wild-
type or Xcl1-deficient recipients, respectively.
Recipient animals were injected 24 hr later with
aDEC-205:OVA or with aDEC-205:OVA in combi-
nation with CD40 mAb. Frequencies of OT-I
T cells in spleens were determined on days 3
and 12 after antigen delivery. A representative
experiment out of three is shown. The mean is indi-
cated as a bar.
(B) Xcl1+/+ or Xcl1/ OT-I T cells were adoptively
transferred into wild-type recipients (top row)
versus Xcl1-deficient animals (bottom row) and
their relative frequencies were determined on
days 3, 6, and 12 after immunization with aDEC-
205:OVA in combination with CD40 mAb (OT-I
frequencies in PBS-injected animals = 100%).
Representative experiment out of two. Data are
presented as mean ± SEM.
(C) Expression of CD69, CD25, and 4-1BB on
Xcl1+/+ (bold histograms) versus Xcl1/ (dotted
histograms) OT-I T cells transferred into wild-
type recipients, which were injected with aDEC-
205:OVA. Shown are the flow cytometry profiles
20 hr after antigen delivery. Representative ex-
periment out of six.
and this effect was independent of XCL1
(Figure 6A). In contrast, after immuniza-
tion with aDEC-205:OVA in combination
with CD40 mAb, Xcl1+/+ OT-I T cells could
be detected at the expected frequency,
whereas the number of Xcl1/ OT-I
T cells was drastically reduced (by an
average of 74%), often to the point that
they were no longer detectable (Fig-
ure 6A). Because the differences in the
frequencies between the experimental
groups could be caused by different kinetics of T cell egress
from the spleen, we determined the presence of OT-I T cells in
the immunization group in various organs on day 12. As shown
in Table S4, the frequencies of Xcl1/ OT-I T cells were highly
reduced in all organs when compared to control OT-I T cells,
indicating that the absence of XCL1 caused a substantial reduc-
tion of the antigen-reactive T cell pool on day 12.
We extended the experiments to control for any contribution of
other cells secreting XCL1 and for any functional changes in CD8+
DCs in Xcl1/ animals. First, we transferred Xcl1+/+ OT-I versus
Xcl1/ OT-I T cells into wild-type recipients and compared their
frequencies in the spleen 3, 6, and 12 after antigen injection. The
frequencies of Xcl1/ OT-I cells did not differ substantially at
3 and 6 days, but were reduced by about 40% on day 12 (Fig-
ure 6B, top row). Upon transfer into Xcl1/ recipients, the pool
size of Xcl1/ OT-I T cells, compared to Xcl1+/+ T cells, was
reduced by about 65% already on day 6, and by 60% on day
12 (Figure 6B, bottom row). These experiments demonstrated
that secretion of XCL1 has major consequences on the resulting
pool size of the CD8+ T cells. At the same time, the reduced828 Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc.
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ients (around 5-fold versus 15-fold on day 3) indicated a reduced
competence of CD8+ DCs for activation of CD8+ T cells in Xcl1-
deficient mice, at least at the early time points. In these animals,
the absence of XCL1 apparently influences the homeostatic acti-
vation or differentiation status of CD8+ DCs.
To assess any contribution of XCL1 to the early activation of
CD8+ T cells interacting with CD8+ DCs, we transferred Xcl1+/+
or Xcl1/ OT-I T cells into wild-type recipients and compared
their activation status at 6, 12, 18, 24, and 48 hr after application
of aDEC-205:OVA. Interestingly, we observed that Xcl1/ OT-I
T cells exhibited a differing activation pattern at around 20 hr,
with higher expression of CD69, CD25, and 4-1BB (Figure 6C).
Although these differences were not dramatic, they were consis-
Figure 7. Influence of XCL1 on the Differen-
tiation of CD8+ T Cells to Effector Cells
(A) In the experiment shown in Figure 6A, spleen
cells were restimulated in vitro with the SIINFEKL
peptide for 5 hr and OT-I T cells were analyzed
for intracellular expression of IFN-g. Shown is the
statistical analysis of three experiments (mean ±
SEM); the frequencies of Xcl1+/+ and Xcl1/ OT-I
T cells capable of secreting IFN-g after injection
with PBS alone were set to 100%.
(B) Xcl1+/+ OT-I or Xcl1/ OT-I T cells were adop-
tively transferred into wild-type recipients and
Xcl1/ OT-I T cells into Xcl1/ recipients and
the animals were injected 24 hr later with the allo-
geneic pre B cell line 300-19 transfected with OVA
(‘‘300-19-OVA’’) or with untransfected 300-19 cells
(control). The splenic frequencies and the OVA-
specific cytotoxic activities of the transferred OT-I
T cell populations were determined on days 6 (top
row) and 12 (bottom row) after antigen delivery.
(C) The development of endogenous, OVA-
specific cytotoxic activity was determined in
wild-type and Xcl1/ animals on day 21 after
injection of 300-19-OVA or 300-19 cells on days
1, 3, and 14. Injection of 300-19 cells gave in no
instance a cytotoxic activity against OVA-loaded
syngeneic target cells. All experiments were per-
formed at least twice. Representative data are
shown. Columns are presented as mean ± SEM;
bars indicate the median.
tently observed in six experiments; at
other time points and with other markers
(CD27, ICOS, PD-1, OX40, BTLA), no
differences were noticed. Similar data
were obtained upon additional injection
of CD40 mAb (not shown). These experi-
ments suggested that XCL1 modifies
the activation status of CD8+ DCs, which
in turns changes the activation pattern of
the interacting CD8+ T cells.
XCL1 Augments the Capacity
of CD8+ T Cells for IFN-g Secretion
and Cytotoxic Activity
To assess the influence of XCL1 on the
differentiation of CD8+ T cells to effector
cells, we measured the capacity of Xcl1+/+ OT-I or Xcl1/ OT-I
T cells to secrete TNF-a, IL-2, and IFN-g in the system of toleriza-
tion and immunization (see Figure 6A). XCL1 did not affect the
secretion capacity of either group of OT-I T cells for IFN-g on
day 3 or in tolerized OT-I T cells on day 12 (Figure 7A). However,
immunized Xcl1/ OT-I T cells exhibited a reduced capacity (by
an average of 44%) to secrete IFN-g on day 12 (Figure 7A). No
major differences were observed for TNF-a and IL-2 (not shown).
In order to examine the influence of XCL1 on CD8+ T cell differ-
entiation in a system independent of antigen targeting via DEC-
205 and costimulation with the CD40 mAb, OVA-transfected
allogeneic pre-B cells (‘‘300-19-OVA’’) were injected i.v. for
antigen delivery. In such a system, the antigenic content of the
cell line is specifically processed and (cross-) presented byImmunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc. 829
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into cytotoxic cells (Law et al., 1977; den Haan et al., 2000; Iyoda
et al. 2002; and our observations). We have examined the influ-
ence of XCL1 on the expansion and differentiation of CD8+
T cells under these conditions. Xcl1+/+ OT-I or Xcl1/ OT-I
T cells were adoptively transferred into wild-type recipients
and Xcl1/ OT-I T cells into Xcl1/ recipients and the animals
were injected 24 hr later with 300-19-OVA cells. No dramatic
differences were observed on the frequencies of the OT-I
T cells in the spleen on day 6 (Figure 7B, top row). However,
12 days after 300-19-OVA injection, the pool size of Xcl1+/+
OT-I T cells was several fold higher when compared to Xcl1/
OT-I T cells transferred into wild-type or Xcl1/ recipients
(Figure 7B, bottom row). Functionally, a very potent OVA-
specific in vivo cytotoxicity could be observed with Xcl1+/+ OT-I
T cells already 6 days after transfer into wild-type recipients,
which in tendency was diminished in transferred Xcl1/
T cells (Figure 7B, top row). On day 12, the differences in cyto-
toxic activity between Xcl1+/+ and Xcl1/ OT-I T cells became
prominent (Figure 7B, bottom row).
The OT-I adoptive transfer system used for the cytotoxicity
experiments gives an increased starting frequency of OVA-
specific T cells and may for this reason not reflect all aspects
of the physiological differentiation of CD8+ T cells into cytotoxic
effectors. We have therefore also tested the endogenous cyto-
toxic response of wild-type and Xcl1/ mice by immunizing
them with the 300-19-OVA cell line. When the development of
OVA-specific cytotoxicity was tested on day 21 in vivo, Xcl1/
mice again exhibited a reduced response (Figure 7C).
DISCUSSION
In the present work, we provide consistent experimental data
for the functional understanding of the chemokine XCL1 and its
receptor XCR1. The basis for this advancement is the demon-
stration of an essentially exclusive expression of XCR1 in murine
CD8+ DCs. XCR1-reporter mice revealed an expression of XCR1
in a large majority (70%–85%) of splenic CD8+ DCs, which coex-
press CD205 and CD103. We could show that XCL1 induces
a calcium flux in CD8+ DCs and acts as a strong and specific
chemoattractant for splenic and LN CD8+ DCs; the negative
results obtained with Xcr1/ CD8+ DCs in these assays indi-
cated that the chemotactic action of XCL1 is mediated solely
through XCR1. Our data show that XCR1+ DCs are located in
the red pulp, the marginal zones, and central areas of T cell
zones of the spleen and the subcapsular sinus of lymph nodes.
In a series of in vivo experiments, we observed that CD8+
T cells secrete XCL1 in a dose-dependent fashion 8–36 hr after
encountering antigen on CD8+ DCs. We could demonstrate
with two independent systems of antigen targeting into CD8+
DCs that XCL1 secretion substantially increases the survival of
CD8+ T cells and their differentiation to IFN-g-secreting effectors
in the first 2 weeks after antigen contact in vivo. Finally and
importantly, absence of XCL1 impaired the development of
antigen-specific cytotoxicity in vivo.
Both our XCR1 expression data and functional results with
XCL1 are at variance with numerous reports in the past. Origi-
nally, XCR1 (cloned as orphan receptor GPR5), when transfected
into a cell line, has been shown to be the only chemokine830 Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc.receptor capable of mediating a calcium signal and chemotaxis
in response to XCL1 (Yoshida et al., 1998, and our unpublished
results). The subsequent search for primary cells expressing
XCR1 has obviously been hampered by several factors. First,
CD8+ DCs represent only a very minor population, approximately
0.2% of splenic cells, which contaminates any isolated cell pop-
ulation unless rigidly removed. Second, all past analyses relied
on PCR systems utilizing mRNA and cDNA encoded by exon 2
only. Thus, trace amounts of genomic DNA typically present in
total RNA preparations easily resulted in false-positive PCR
signals for XCR1 mRNA in many tissues, also in our hands
(Dorner et al., 2002). Only the use of polyA-RNA or a qRT-PCR
system spanning the intron-exon boundaries of the XCR1 gene
eliminated this problem and revealed a selective expression of
XCR1 in CD8+ DCs. Finally, immature and LPS-matured bone-
marrow-derived DCs, very often used for studies in vitro, do
not express XCR1 mRNA (data not shown). The description of
XCL1 as a chemokine attracting T cells, B cells, NK cells, and
other cell types was already disputed in the past (see Table
S1; Dorner et al., 1997; Yoshida et al., 1998; Bleul et al., 1996).
The failure to detect XCR1 mRNA in these populations with
a highly sensitive assay makes XCL1 an unlikely chemoattrac-
tant for these cell populations, unless one would postulate
a second receptor for XCL1. There is, however, no evidence
for such a second receptor, and the original recognition of
XCR1 and XCL1 as a monogamous ligand-receptor system
has been confirmed (Yoshida et al., 1998). In fact, we could
demonstrate with Xcr1/ cells that XCL1 exerts its chemotaxis
on CD8+ DCs exclusively via XCR1. Moreover, in the same
assays in which XCL1 exhibited potent chemoattraction on
CD8+ DCs, no effect was seen on T cells, B cells, or NK cells.
In the steady state and also after antigen targeting (aDEC-
205:OVA ± aCD40) and recognition, XCR1+ DCs, along with
other CD11c+ DCs, are located in the same or in neighboring
anatomical subregions of spleen and LN as CD8+ T cells, sug-
gesting that XCL1 exerts its function mainly at short distances
within immune tissues. It has been proposed that communica-
tion between CD8+ T cells and DCs starts with a phase of
unstable interactions (around 0–10 hr), and is followed by a phase
of prolonged interactions (around 10–20 hr) and another phase of
unstable interactions (20–30 hr) (Mempel et al., 2004). The very
abundant expression of XCL1 with a peak at 12 hr strongly
suggests that the chemokine XCL1 is one of the factors inducing
prolonged interactions between CD8+ T cells and CD8+ DCs. A
positive correlation between the duration of antigen exposure
and the final pool size of antigen-reactive CD8+ T cells (Prlic
et al., 2006; Tewari et al., 2006) has recently been demonstrated.
XCL1 most likely increases the effective ‘‘antigen recognition
time’’ for CD8+ T cells, because absence of XCL1 very substan-
tially reduces the number of surviving antigen-reactive T cells
and impairs the development of cytotoxicity. Moreover, XCL1
has the potential to attract neighboring CD8+ DCs to the site of
first antigen encounter, because XCR1+ CD8+ DCs are capable
of migrating within splenic tissue compartments (our unpub-
lished data); an incoming antigen could thus be taken up and
presented by a larger population of CD8+ DCs. XCL1 thus is
a candidate factor for the subdomain organization of CD8+
T cell-DC interactions postulated as essential for an efficient
immune response (Germain et al., 2008). Moreover, the high
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amount of secreted XCL1 offers an additional regulatory feed-
back system. In contrast to the contribution of CD8+ DCs to
the regulation of T cell-DC interaction, e.g., induced by Toll-like
receptor ligands, such a regulatory loop would be strictly antigen
dependent. Together, XCL1 may thus act at multiple points to
optimize antigen uptake, processing, and recognition by
T cells in cytotoxic Th1 cell immunity.
Independent of its function, the exclusive expression of XCR1
on CD8+ DCs has a number of interesting implications. For first, it
allows researchers to develop experimental strategies to delete
CD8+ DCs in vivo, either temporally or permanently, and work of
this type is under way. Maybe even more intriguing, XCR1 could
be used to target antigens to CD8+ DCs. It has been elegantly
demonstrated that delivery of antigen to CD8+ DCs via DEC-
205 very efficiently induces CD8+ T cell responses (Bonifaz
et al., 2002). The loading of CD8+ DCs may be needed to develop
potent Th1 cell immunity against certain infections and also
tumors, where conventional vaccines (which mainly induce
protective antibodies) fail (Figdor et al., 2004). The highly selec-
tive expression of XCR1 on CD8+ DCs and the typical internaliza-
tion of chemokine receptors upon ligand binding make XCR1
a potentially ideal entry port for Th1 cell vaccines.
EXPERIMENTAL PROCEDURES
Cells, Mice, and Adoptive Transfer of T Cells
Cells were isolated, unless indicated otherwise, from C57BL/6 mice. For
generation of Xcl1-deficient mice, exons 2 and 3 of the Xcl1 gene were
replaced by a neomycin resistance cassette in 129SV embryonic stem cells
via the targeting vector pTV-0 (Riethmacher et al., 1995); the remaining intact
exon 1 codes only for the signal peptide. Xcl1/ mice were backcrossed to
the C57BL/6 background for 10 generations. OT-I TCR-transgenic mice (Hog-
quist et al., 1994) were crossed onto B6.PL mice to allow identification of
adoptively transferred cells with the CD90.1 marker, and further crossed to
Xcl1-deficient mice. B6.XCR1-lacZ mice were obtained from The Jackson
Laboratories. For adoptive transfer experiments, splenocytes from 8- to
10-week-old female donors containing 2.53 106 OT-I T cells (unless indicated
otherwise) were injected i.v. alone or together with 6 mg of CD40 mAb FGK into
female recipients of the same age. All mice were bred under specific-path-
ogen-free conditions in the animal facility of the Federal Institute for Risk
Assessment (Berlin, Germany), and experiments were performed according
to state guidelines and approved by the local ethics committee.
Antibodies
Antibodies recognizing CD8 (clone 53-6.72), CD4 (GK1.5), CD19 (1D3), CD11b
(5C6), CD11c (N418), and MHC-class II (M5/114.15.2) were from ATCC;
CD90.1 (OX-7) from ECACC; F4/80 (BM8), CD69 (H1.2F3), CD3 (145-2C11),
Ly-6G/C (RB6-8C5), and CD317 (PDCA-1) from eBioscience; and NK1.1
(PK136) and CD103 (M290) from BD Biosciences. IFN-g was stained with
mAb AN-18 (eBioscience), XCL1 with mAb MTAC-2, generated by immunizing
Lewis rats with His-tagged murine XCL1 (Val22-Gly114). aDEC-205 (NLDC-145,
CD205) was generously provided by G. Kraal (Amsterdam), aCD40 (FGK) by T.
Rolink (Basel), aCD3 (KT3) by H. Savelkoul, aCD25 (2E4) by E. Shevach, and
aCD28 (37.51) by J. Allison. Conjugation of LPS-free ovalbumin (Sigma) to
aDEC-205 mAb was performed as described (Bonifaz et al., 2004).
Flow Cytometry and Cell Sorting
Adoptively transferred OT-I cells were identified by expression of CD90.1.
Staining for surface antigens was performed with directly conjugated anti-
bodies. For intracellular staining of XCL1, spleen cells were incubated
in vitro with Brefeldin A (5 mg/ml) for 3 hr, without restimulation; for IFN-g stain-
ing, cells were restimulated in vitro with the peptide SIINFEKL (50 ng/ml) for
5 hr in the presence of Brefeldin A. Cells were then fixed with 2% formalde-hyde, washed, incubated in 0.5% saponin, and stained for either cytokine.
For LacZ reporter analysis, cells were incubated with fluorescein-di-b-D-gal-
actopyranoside (Invitrogen) according to the manufacturer’s instructions.
Data were acquired on a LSR II flow cytometer (BD Biosciences) and analyzed
with FlowJo (Tree Star Inc.). Flow-sorting of cells was performed on an Aria Cell
Sorter (BD Biosciences).
Histological Analysis
Organs from Xcl1-deficient mice and B6.XCR1-lacZ+/+ mice (LNs, spleen,
Peyer’s patches, thymus, liver, kidney, intestine, lung, heart, salivary gland,
suprarenal gland, brain) were histologically examined and immune cells
were extensively analyzed. Organs from both mice showed no obvious devel-
opmental defects. For the analysis of b-galactosidase activity, splenic and
lymph node tissues from homozygous or heterozygous B6.XCR1-lacZ+/+
mice were fixed with 0.1% glutaraldehyde plus 4% paraformaldehyde in
PBS for 4 hr at RT, immersed in 10% sucrose overnight, and snap-frozen in
0.9% NaCl. Cryosections were washed 33 with cold PBS (pH 7.4) for 5 min
after thawing, incubated with X-Gal staining solution (Sanes et al., 1986) over-
night at 37C, washed 33 with PBS, and counterstained with Neutral Red.
Quantitative PCR
For isolation of total RNA, CD4+ T cells (CD3+CD4+, 99% pure), CD8+ T cells
(CD3+CD8+, 99%), B cells (CD19+, 95%), and NK cells (NK1.1+DX5+, 92%)
were flow-sorted from spleen cells with a strategy ensuring absence of
CD8+ DCs. CD8+ DCs (CD11c+MHC-IIhiCD8+, 99%) and CD8 DCs
(CD11c+MHC-IIhiCD8, 99%) were flow-sorted from spleen cells after enrich-
ment on a Nycoprep density gradient (1.077 g/ml, Fresenius Kabi, Norway),
pDC (PDCA-1+B220+CD11intMHC-IIint, 99%) after enrichment with PDCA-1
magnetobeads (Miltenyi). CD4+ and CD8+ T cells (105 cells in 100 ml complete
cell culture medium) were activated for 3 days in 96-well plates (Costar #3366)
coated with CD3 mAb (145-2C11) at 0.5 mg/ml and CD28 mAb (37.51) at
4 mg/ml, B cells (83 106 in 4 ml) were activated by CD40 mAb (FGK, 10 mg/ml)
and LPS (5 mg/ml, Sigma L-6529) at 37C for 48 hr, NK cells (1.63 106 in 5 ml)
with recombinant IL-2 (1600 U/ml) at 37C for 2 days. Immature and LPS-
matured bone marrow-derived DCs were generated as described earlier
(Lutz et al., 1999). Total RNA was prepared with the High Pure RNA Isolation
Kit (Roche Diagnostics), poly(A)RNA with the mMACS mRNA Isolation Kit (Mil-
tenyi). RNA concentration, purity, and integrity were determined on the Agilent
2100 bioanalyzer (Agilent Technologies) and by photometrical reading (Nano-
Drop 1000). For quantitative determination of XCR1 expression in tissues, 1 mg
of total RNA was reverse-transcribed into cDNA with hexamer primers and the
AMV Reverse Transcription System (Promega). The cDNA was analyzed by
qPCR for its content of XCR1 copies with two different primer probe sets:
50-CCTACGTGAAACTCTAGCACTGG-30 (forward, F1), 50-AAGGCTGTAGAG
GACTCCATCTG-30 (reverse, R1), and 50-FAM-TACAGACTTGAAACCC-
MGB-30 (probe, P1); this test system allowed detection of R200 copies of
XCR1 in cDNA reverse-transcribed from 1 mg of total RNA. The second
qPCR set was used for analysis of poly(A)RNA: 50-TGCCTGTGTTGATCTCA
GCAC-30 (forward, F2), 50-CGGTGGATGGTCATGATGG-30 (reverse, R2),
50-FAM-CATCAGCCTCTACAGCAGCATCTTCTTCCT-TAMRA-30 (probe, P2).
Amplification of b2-microglobulin was used as a control: 50-ATTCACCC
CCACTGAGACTGA-30 (forward), 50-CTCGATCCCAGTAGACGGTC-30 (re-
verse), and 50-FAM-TGCAGAGTTAAGCATGCCAGTATGGCCG-TAMRA-30
(probe). To generate a standard for mRNA and cDNA copy quantification,
the specific XCR1 gene fragment was amplified and cloned into pJET1.2
with the CloneJET PCR cloning kit (Fermentas). For quantitative PCR, primers
were mixed with 10 ml ABsolute QPCR Mix including ROX (ABgene) and 1/10th
of the cDNA in a 20 ml PCR-reaction. PCR was performed and quantified on the
Mx3000P QPCR System from Stratagene with initial enzyme activation for
15 min at 95C followed by 40 cycles (95C, 15 s; 60C, 1 min). Standard
PCR for murine XCR1 was performed with the Phusion Hot Start High-Fidelity
DNA Polymerase (Finnzymes) in a 50 ml volume with primers F1 and R1 with
initial denaturation for 30 s at 98C followed by 40 cycles (98C, 10 s; 60C,
30 s; 72C, 30 s) and a 10 min delay at 72C.
Fluorometric [Ca2+]i Determination
CD8+ and CD8 DCs, freshly flow-sorted to a purity >96% with mAb to CD8,
CD11b, CD11c, and MHC-class II, were supplemented with 2 mM fura-2/AMImmunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc. 831
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slips at 37C and 5% CO2 for 30 min in a humidified atmosphere. Adherent
cells were superfused with a HEPES-buffered solution containing 128 mM
NaCl, 6 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5.5 mM glucose, 10 mM HEPES,
0.2% BSA, and mounted onto the stage of an inverted microscope (Axiovert
100, Zeiss). During application of 1000 ng/ml XCL1, fura-2 was sequentially
excited with monochromatic light of 340 nm, 358 nm, 380 nm, and 480 nm,
and fluorescence emission was detected through a 512 nm long pass filter
with a cooled CCD-camera (TILL-Photonics), [Ca2+]i was calculated after
spectral unmixing (Lenz et al., 2002).
Chemotaxis Assay
Spleens or popliteal and inguinal LNs of C57/BL6 mice were cut into small
pieces and digested with Collagenase D (500 mg/ml) and DNase I (20 mg/ml,
both Roche, Mannheim, Germany) for 25 min at 37C in RPMI 1640 containing
2% FCS (low endotoxin, Biochrom, Berlin, Germany), EDTA (10 mM) was
added for additional 5 min and cells were filtered through a 70 mm nylon sieve
(BD Falcon). DCs were enriched (purity > 90%) by centrifugation over a Nyco-
prep density gradient (1.077 g/ml), followed by magnetic cell sorting with
aCD11c microbeads (Miltenyi). T cells (>98% CD3+) were magnetically sorted
from spleen cells with aCD90 beads, B cells (>97%) with biotinylated CD19
mAb and anti-biotin beads. NK cells (>60% NK1.1+) were obtained by deple-
tion of splenic cells with biotinylated CD3, CD19, and Ly-6G/C mAb, followed
by anti-biotin beads (Miltenyi).
For migration assays, cells (0.5–1 3 106) suspended in 100 ml chemotaxis
medium (RPMI 1640, 1% BSA, 50 mM b-ME, 100 mg/ml penicillin/streptomycin)
were placed into the upper chamber of a 24 Transwell system (6.5 mm diam-
eter, 5 mm pore polycarbonate membrane, Corning Costar Co., Acton, MA,
USA). The lower chamber was filled with chemotaxis medium containing
chemically synthesized murine XCL1 (Dictagene, Lausanne, Switzerland), or
any of the control chemokines CCL21, CXCL12, and CXCL9 (all R&D Systems).
Cells were incubated for 120–150 min at 37C in 5% CO2. The cells in the lower
chamber were analyzed by flow cytometry for the expression of CD8, CD11b,
and CD11c (DCs), CD3 (T cells), CD19 (B cells), and NK1.1 (NK cells). The
absolute number of input or migrated cells was determined by counting cells
in a defined volume via a flow cytometer. The percentage of migrated cells
was calculated by dividing the number of cells in the lower chamber by the
number of input cells (number migrated cells/number input cells 3 100). All
experiments were performed with duplicate wells.
Ovalbumin-Expressing Cell Line
The cDNA encoding amino acids 138–386 of OVA (‘‘DOVA’’) was cloned
in-frame with the Yellow Fluorescent Protein into the pcDNA3 vector (Invitro-
gen) and verified by sequencing. A stable line expressing the truncated,
nonsecreted form of OVA (‘‘300-19-OVA’’) was obtained with the DOVA-
YFP-pcDNA3 vector by electroporation of the pre-B cell line 300-19 (Alt
et al., 1981), followed by subcloning of YFP-expressing cells under limiting
dilution conditions.
In Vivo Cytotoxicity Assay
For cytotoxicity assays in the adoptive transfer system, Xcl1+/+ or Xcl1/ OT-I
T cells (1 3 106) from female mice were transferred into female recipients,
which were injected 24 hr later with 300-19 or 300-19-OVA cells (3 3 106)
i.v. For induction of endogenous cytotoxicity, animals were repeatedly injected
with 300-19 or 300-19-OVA cells (0.3 or 13 106) i.v. After the indicated immu-
nization periods, the in vivo cytotoxicity assay was performed. To this end,
splenocytes from female wild-type C57BL/6 mice were incubated at 30 3
106 cells/ml in complete RPMI medium alone or with SIINFEKL peptide
(10 mg/ml) for 2 hr. The cells were washed and incubated at 50 3 106 cells/
ml in the dark with CFSE (Molecular Probes Europe, Breda), either at 1.5 mM
(unpulsed cells; CFSElo) or 15 mM (peptide-pulsed cells; CFSEhi) for 15 min
at 37C, washed, and resuspended in PBS at 100 3 106 cells/ml. Twenty
million cells of a 1:1 mixture of CFSElo:CFSEhi were adoptively transferred
into test mice, and 18 hr later the splenocytes of test mice were analyzed by
flow cytometry. The percentage of target cell killing was calculated with the
formula: 100  (((% relevant peptide-pulsed in immunized/% irrelevant pep-
tide-pulsed in immunized)/(% relevant peptide-peptide pulsed in control/%
irrelevant peptide-pulsed in control)) 3 100). The injection of untransfected832 Immunity 31, 823–833, November 20, 2009 ª2009 Elsevier Inc.300-19 cells gave in no instance a signal in the OVA-specific cytotoxicity
assay.
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